权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Cardiac Macrophages as Disease Drivers in Chronic Ischemic Heart Failure

心脏巨噬细胞作为慢性缺血性心力衰竭的疾病驱动因素

基本信息

批准号：
10592811
负责人：
Sumanth D Prabhu
金额：
$ 52.62万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-04-01 至 2025-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10592811
关键词：
Acute Adoptive Cell Transfers Adoptive Transfer Antibodies Antisense Oligonucleotides Attenuated Behavior Biological Assay Biological Response Modifiers Bone Marrow C57BL/6 Mouse Cardiac Cell Proliferation Cell Separation Cells Cellular Indexing of Transcriptomes and Epitopes by Sequencing Characteristics Chronic Classification Clinical Congestive Heart Failure Coronary Data Disease Disease Progression Disease model Exhibits Female Fibrosis Flow Cytometry Functional disorder Genes Genetic Transcription Heart Heart Injuries Heart failure Human Immune Immunohistochemistry Inflammation Inflammatory Injections Interleukin Receptor Interleukin-10 Interleukin-13 Interleukin-4 Interleukins Knockout Mice Late Effects Left Ventricular Remodeling Ligation Link Measures Mediator of activation protein Modeling Mus Myelogenous Myocardial Infarction Myocardial Ischemia Myocarditis Myocardium Myofibroblast PTPRC gene Pathogenesis Pathologic Pathway interactions Phagocytes Phagocytosis Population Prognosis Progressive Disease Proliferating Proteins Role Signal Pathway Signal Transduction Source Spatial Distribution Tamoxifen Testing Therapeutic Tissue Expansion Tissues beta-Chemokines cardiogenesis cell type chemokine chemokine receptor cytokine gamma-Chemokines heart cell immune activation immunomodulatory strategy immunoregulation in vivo innovation insight ischemic cardiomyopathy kinase inhibitor macrophage male monocyte neutralizing antibody novel novel strategies recruit repaired self renewing cell self-renewal single-cell RNA sequencing small molecule targeted treatment therapeutic target tissue injury transcriptomics virtual

项目摘要

Macrophage expansion in the failing heart induces tissue injury and is thought to contribute to the progression of heart failure (HF). The main contributors to macrophage expansion in the failing heart are cells that self-renew and proliferate independent of the blood monocyte pool (and hence are C-C chemokine receptor 2 [CCR2]–). However, the role of such locally-sourced macrophages in the pathogenesis of chronic left ventricular (LV) remodeling is poorly understood. The normal heart harbors macrophages expressing CD206 (Mrc1), along with the gene markers Ym1, Fizz1, and Arg1, that are primarily CCR2–. These CD206+ macrophages can be activated by Th2 cytokines such as interleukin(IL)-4/IL-13. Moreover, secreted FIZZ1 contributes to myofibroblast activation and fibrosis in other disease models. Our pilot data indicate that CD206+ macrophages expressing IL- 4 receptora (IL-4Ra) robustly increase in the failing heart, and suggest that macrophage IL-4/IL-4Ra signaling promotes LV remodeling and fibrosis, in part through FIZZ1. Hence, we hypothesize that cardiac CD206+ macrophages expressing IL-4Ra and Fizz1 are innate immune mediators of adverse LV remodeling in chronic HF, and key targets for therapeutic immunomodulation. Three Aims will test this hypothesis. In Aim 1, in a murine coronary ligation model, using flow cytometry, cell sorting, single cell RNA sequencing (scRNAseq), and immunohistochemistry, we will comprehensively define pathological alterations in cardiac CD206+ macrophages in HF, including IL-4Ra levels and downstream signaling, FIZZ1 expression, and in vivo cell abundance, proliferation, turnover and phagocytic capacity. Using scRNAseq, we will define novel functional subpopulations of CD206+ macrophages at the transcriptional level in both murine and human failing hearts. In Aim 2, we will establish the pathogenetic role of CD206+IL-4Ra+ macrophages in HF using CD45.2 inducible myeloid-specific IL-4Ra knockout mice, deleting myeloid IL-4Ra during chronic HF, and assessing the late effects on LV remodeling, inflammation, and fibrosis. To establish sufficiency of failing heart CD206+IL-4Ra+ macrophages to induce tissue injury, we will adoptively transfer sorted cardiac CD206+ macrophages with intact or deleted IL- 4Ra from HF mice into naïve CD45.1 mice via intramyocardial injection and assess LV remodeling 6 w later. To assess the role of FIZZ1, we will similarly transfer M[IL-4] polarized bone marrow macrophages from wild-type and Fizz1-/- mice. In Aim 3, we will test potentially translatable therapies to antagonize CD206+IL-4Ra+ macrophages and alleviate chronic LV remodeling, including systemic anti-sense oligonucleotides against IL- 4Ra and Fizz1, anti-IL-4 neutralizing antibody, and GW2580, a small molecule cFMS kinase inhibitor. We will measure the effects of these therapies on LV remodeling, cardiac macrophages, fibrosis, and chemokine/ cytokine expression. These studies will further our understanding of the innate immune basis for cardiac inflammation in ischemic HF, provide novel insights into macrophage IL-4-dependent signaling and Fizz1 in the pathogenesis of LV remodeling, and identify new approaches for cell type-specific immunomodulation in HF.

巨噬细胞在衰竭心脏的扩张诱导组织损伤，并被认为有助于进展